The effect of rituximab on vaccine responses in patients with immune thrombocytopenia Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key PointsAfter treatment with rituximab, immunological responses to both polysaccharide and conjugated vaccines are impaired in patients with ITP. Splenectomized patients who received rituximab may be at increased risk of infection because of compromised immune responses to vaccines.

authors

status

published

publication date

September 12, 2013

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Adult (MeSH)
Aged (MeSH)
Antibodies, Bacterial (MeSH)
Antibodies, Monoclonal, Murine-Derived (MeSH)
B-Lymphocyte Subsets (MeSH)
Bacterial Capsules (MeSH)
Combined Modality Therapy (MeSH)
Double-Blind Method (MeSH)
Drug Therapy, Combination (MeSH)
Female (MeSH)
Haemophilus Vaccines (MeSH)
Haemophilus influenzae type b (MeSH)
Humans (MeSH)
Immunity, Cellular (MeSH)
Immunology (Science Metrix)
Interferon-gamma (MeSH)
Male (MeSH)
Middle Aged (MeSH)
Prospective Studies (MeSH)
Rituximab (MeSH)
T-Lymphocytes (MeSH)
Thrombocytopenia (MeSH)
Treatment Outcome (MeSH)

published in

Blood Journal